Wall Street is positive on Seelos Therapeutics Inc (SEEL). On average, analysts give Seelos Therapeutics Inc a Strong Buy rating. The average price target is $9.5, which means analysts expect the stock to gain by 486.42% over the next twelve months. That average ranking earns Seelos Therapeutics Inc an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating SEEL a Strong Buy today. Find out what this means to you and get the rest of the rankings on SEEL!